JAK2 and acquired polycythemia vera: Altogether, these preliminary results obtained in a small subset of patients included in the PROUD-PV study must be confirmed in larger numbers, but they suggest that IFNα could be a good candidate for achieving long-term eradication of JAK2-mutant clones and restoring normal hematopoiesis in PV patients.